Summary

Middle East STD Diagnostics Market Summary

The Middle East STD diagnostics market size was estimated at USD 216.56 million in 2024 and is projected to reach USD 390.96 million by 2033, growing at a CAGR of 6.75% from 2025 to 2033. Rising incidence of sexually transmitted infections such as HIV, syphilis, gonorrhea, and chlamydia, along with limited early detection in some countries, is driving demand for accurate and timely diagnostic solutions in the region. Developments in molecular testing technologies, wider adoption of rapid and point-of-care testing, and improvements in multiplex assay platforms are supporting market expansion. In addition, national programs aimed at disease prevention, targeted screening campaigns, and healthcare investments in both public and private sectors are contributing to the growing demand for STD diagnostics.

Advances in nucleic acid amplification tests (NAAT), integration of automated platforms, and increased availability of self-testing kits are reshaping the STD diagnostics landscape in the Middle East. Regulatory bodies in countries such as Saudi Arabia and the UAE are updating in-vitro diagnostic (IVD) guidelines to streamline approval processes and ensure quality standards, which is expected to accelerate product availability. Growing awareness through public health campaigns, expansion of screening in antenatal and primary care settings, and collaborative initiatives with global health organizations are further supporting early detection efforts. These developments, combined with rising private healthcare expenditure and the presence of international diagnostic manufacturers, are creating opportunities for market growth across the region.

Surveillance data from the region indicate a sustained burden of sexually transmitted infections that continues to drive the need for improved diagnostics. In Saudi Arabia, the Tabuk Region recorded 290 notified STI cases up to 19 November 2024, with vulvovaginal candidiasis accounting for 35% (102 cases) and urethral discharge syndrome at 14.8% (43 cases)-almost two-thirds of cases were among females (64.8%) and Saudi nationals (88.4%). These figures reflect ongoing challenges in detection and timely treatment, particularly in community and primary care settings. Similar trends are being addressed in the UAE, Kuwait, Oman, and Qatar through targeted screening initiatives, integration of rapid testing in clinical workflows, and public health awareness campaigns aimed at reducing stigma and promoting early diagnosis.

Overall, innovation in the Middle East STD diagnostics market is centered on improving accessibility, accuracy, and speed of detection to address both clinical and public health needs. The combination of advanced molecular platforms, discreet self-testing options, and integration of rapid devices into primary care workflows is reshaping diagnostic pathways. Digital connectivity is enabling better surveillance and linkage to care, while portable solutions are extending testing capabilities to remote and underserved populations. These developments are not only enhancing diagnostic efficiency but also supporting national goals for early detection and disease control across the region.

Middle East STD Diagnostics Market Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Middle East STD diagnostics market based on product, application, technology, location of testing, and country:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Instruments & Services
• Consumables (Reagents and kits)
• Software
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Chlamydia testing
• Syphilis testing
o PCR testing
o Non-PCR testing
• Gonorrhea testing
• HSV testing
o PCR testing
o Non-PCR testing
• HPV testing
• HIV testing
• Trichomonas
• Ureaplasma + Mycoplasma
• VZV
o PCR testing
o Non-PCR testing
• Others
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Molecular Diagnostics
• Immunoassay
• Others
• Location of Testing Outlook (Revenue, USD Million, 2021 - 2033)
• Laboratory Testing
o Commercial/Private Labs
o Public Health Labs
• PoC testing
• Country Outlook (Revenue, USD Million, 2021 - 2033)
• Middle East
o Saudi Arabia
o UAE
o Kuwait
o Oman
o Qatar

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Middle East STD Diagnostics Market: Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Product Segment
1.1.1.2. Application Segment
1.1.1.3. Technology segment
1.1.1.4. Location of testing
1.2. Country Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
Chapter 2. Middle East STD Diagnostics Market: Executive Summary
2.1. Market Snapshot
2.2. Product and Application Snapshot
2.3. Technology and Location of Testing Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. Middle East STD Diagnostics Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
3.4.1. Rising awareness and government initiatives for early detection and prevention of STDs.
3.4.2. Growing adoption of rapid and point-of-care testing solutions for timely diagnosis.
3.4.3. Investments in molecular diagnostics and advanced laboratory infrastructure across the region.
3.5. Market Restraint Analysis
3.5.1. Social stigma and cultural barriers surrounding STD testing in certain Middle Eastern countries.
3.5.2. Limited accessibility to diagnostic facilities in remote or rural areas.
3.6. Porter’s Five Forces Analysis
3.7. PESTLE Analysis
3.8. Pipeline Analysis
Chapter 4. Middle East STD Diagnostics Market: Product Estimates & Trend Analysis
4.1. Middle East STD Diagnostics Market: Product Movement Analysis
4.2. Instruments & Services
4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3. Consumables (Reagents and kits)
4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4. Software
4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Middle East STD Diagnostics Market: Application Estimates & Trend Analysis
5.1. Middle East STD Diagnostics Market: Application Movement Analysis
5.2. Chlamydia testing
5.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.3. Syphilis testing
5.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.3.2. PCR testing
5.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.3.3. Non-PCR testing
5.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4. Gonorrhea testing
5.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. HSV testing
5.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5.2. PCR testing
5.5.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5.3. Non-PCR testing
5.5.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. HPV testing
5.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. HIV testing
5.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.8. Trichomonas
5.8.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.9. Ureaplasma + Mycoplasma
5.9.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.10. VZV
5.10.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.10.2. PCR testing
5.10.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.10.3. Non-PCR testing
5.10.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.11. Others
5.11.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Middle East STD Diagnostics Market: Technology Estimates & Trend Analysis
6.1. Middle East STD Diagnostics Market: Technology Movement Analysis
6.2. Molecular Diagnostics
6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3. Immunoassay
6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4. Others
6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Middle East STD Diagnostics Market: Location of Testing Estimates & Trend Analysis
7.1. Middle East STD Diagnostics Market: Location of Testing Movement Analysis
7.2. Laboratory Testing
7.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.2.2. Commercial/Private Labs
7.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.2.3. Public Health Labs
7.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3. PoC testing
7.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Middle East STD Diagnostics Market: Country Business Analysis
8.1. Country Market Snapshot
8.2. Middle East
8.2.1. Middle East STD Diagnostics Market, 2021 - 2033 (USD Million)
8.2.2. Saudi Arabia
8.2.2.1. Saudi Arabia STD Diagnostics Market, 2021 - 2033 (USD Million)
8.2.2.2. Key Country Dynamics
8.2.2.3. Regulatory Framework
8.2.2.4. Reimbursement Scenario
8.2.2.5. Competitive Scenario
8.2.3. UAE
8.2.3.1. UAE STD Diagnostics Market, 2021 - 2033 (USD Million)
8.2.3.2. Key Country Dynamics
8.2.3.3. Regulatory Framework
8.2.3.4. Reimbursement Scenario
8.2.3.5. Competitive Scenario
8.2.4. Kuwait
8.2.4.1. Kuwait STD Diagnostics Market, 2021 - 2033 (USD Million)
8.2.4.2. Key Country Dynamics
8.2.4.3. Regulatory Framework
8.2.4.4. Reimbursement Scenario
8.2.4.5. Competitive Scenario
8.2.5. Oman
8.2.5.1. Oman STD Diagnostics Market, 2021 - 2033 (USD Million)
8.2.5.2. Key Country Dynamics
8.2.5.3. Regulatory Framework
8.2.5.4. Reimbursement Scenario
8.2.5.5. Competitive Scenario
8.2.6. Qatar
8.2.6.1. Qatar STD Diagnostics Market, 2021 - 2033 (USD Million)
8.2.6.2. Key Country Dynamics
8.2.6.3. Regulatory Framework
8.2.6.4. Reimbursement Scenario
8.2.6.5. Competitive Scenario
Chapter 9. Competitive Landscape
9.1. Company Categorization
9.2. Strategy Mapping
9.2.1. New product launch
9.2.2. Partnerships
9.2.3. Acquisition
9.2.4. Collaboration
9.2.5. Funding
9.3. Key Company Market Share Analysis, 2024
9.4. Company Heat Map Analysis
9.5. Company Profiles
9.5.1. BD
9.5.1.1. Company Overview
9.5.1.2. Financial Performance
9.5.1.3. Type Benchmarking
9.5.1.4. Strategic Initiatives
9.5.2. F. Hoffmann-La Roche Ltd
9.5.2.1. Company Overview
9.5.2.2. Financial Performance
9.5.2.3. Type Benchmarking
9.5.2.4. Strategic Initiatives
9.5.3. Hologic Inc.
9.5.3.1. Company Overview
9.5.3.2. Financial Performance
9.5.3.3. Type Benchmarking
9.5.3.4. Strategic Initiatives
9.5.4. Abbott
9.5.4.1. Company Overview
9.5.4.2. Financial Performance
9.5.4.3. Type Benchmarking
9.5.4.4. Strategic Initiatives
9.5.5. Cepheid (Danaher)
9.5.5.1. Company Overview
9.5.5.2. Financial Performance
9.5.5.3. Type Benchmarking
9.5.5.4. Strategic Initiatives
9.5.6. Qiagen
9.5.6.1. Company Overview
9.5.6.2. Financial Performance
9.5.6.3. Type Benchmarking
9.5.6.4. Strategic Initiatives
9.5.7. OraSure Technologies, Inc.
9.5.7.1. Company Overview
9.5.7.2. Financial Performance
9.5.7.3. Type Benchmarking
9.5.7.4. Strategic Initiatives
9.5.8. Bio-Rad Laboratories, Inc.
9.5.8.1. Company Overview
9.5.8.2. Financial Performance
9.5.8.3. Type Benchmarking
9.5.8.4. Strategic Initiatives
9.5.9. bioMérieux SA
9.5.9.1. Company Overview
9.5.9.2. Financial Performance
9.5.9.3. Type Benchmarking
9.5.9.4. Strategic Initiatives
9.5.10. Thermo Fisher Scientific, Inc.
9.5.10.1. Company Overview
9.5.10.2. Financial Performance
9.5.10.3. Type Benchmarking
9.5.10.4. Strategic Initiatives
9.5.11. Seegene Inc.
9.5.11.1. Company Overview
9.5.11.2. Financial Performance
9.5.11.3. Type Benchmarking
9.5.11.4. Strategic Initiatives
9.5.12. DiaSorin S.p.A
9.5.12.1. Company Overview
9.5.12.2. Financial Performance
9.5.12.3. Type Benchmarking
9.5.12.4. Strategic Initiatives